7743-27-3

Usage

Uses

Used in Organic Synthesis:
(4-cyanobutyl)(triphenyl)phosphonium is used as a phase-transfer catalyst, enabling the transfer of reactants or products from one phase to another. This facilitates various organic synthesis reactions and improves their efficiency.
Used in Production of Organic Compounds:
(4-cyanobutyl)(triphenyl)phosphonium serves as a reagent in the production of various organic compounds, contributing to the synthesis of a wide range of chemical products.
Used in Antimicrobial and Antifungal Applications:
(4-cyanobutyl)(triphenyl)phosphonium has been studied for its antimicrobial and antifungal properties, making it a potential candidate for use in applications that require the control of microbial growth.
Used in Development of New Materials:
(4-cyanobutyl)(triphenyl)phosphonium has been investigated for its potential application in the development of new materials, such as ionic liquids and polymer electrolytes, which can be utilized in various industries including energy storage and electronic devices.

Upstream product

• 5414-21-1 5-bromopentan-1-nitrile 
• 603-35-0 triphenylphosphine 

Downstream Products

• 493009-89-5 α-allyl-N-benzyloxycarbonylpiperidine 
• 117833-94-0 (Z)-(R)-N-Cbz-2,2-dimethyl-4-(5-cyano-1-pentenyl)oxazolidine 
• 158478-66-1 N-allyl-6-(4-t-butylphenyl)hex-5-enylamine 
• 158478-58-1 cis-N-allyl-N-(benzenesulfenyl)-6-(4-t-butylphenyl)hex-5-enylamine 
• 158478-65-0 cis-6-(4-t-butylphenyl)hex-5-enylamine 
• 133298-55-2 6-(4-(2-(4-chlorobenzenesulphonylamino)ethyl)-phenyl)-6-(pyridin-3-yl)hex-5-enoic acid 
• 174627-05-5 N-benzenesulfonyl-3-(7-cyano-3-heptenyl)-5,6-dihydro-2(1H)-pyridinone 
• 217454-35-8 (Z)-7-hydroxy-4'-(trifluoromethyl)-5-heptenophenone 
• 217454-44-9 (Z)-7-bromo-4'-(trifluoromethyl)-5-heptenophenone 
• 217454-37-0 (Z)-7-hydroxy-4'-(methylsulfonyl)-5-heptenophenone 
• 217454-47-2 (Z)-7-bromo-4'-(methylsulfonyl)-5-heptenophenone 
• 217454-34-7 (Z)-7-hydroxy-4'-(methylthio)-5-heptenophenone 
• 217454-52-9 (E)-7-hydroxy-4'-methoxy-5-heptenophenone 
• 217454-33-6 (Z)-7-hydroxy-4'-methoxy-5-heptenophenone 

Relevant academic research and scientific papers

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

Diels-Alder reaction of the dihydropyridinones V: Approach to the ircinal B core

Thermal and high-pressure Diels-Alder reaction of the suitably assembled dihydropyridinones afforded the hydroisoquinoline derivatives, which were transformed to the key intermediates for the ABC substructure of ircinal B.

Synthesis of pyrrolizidines using aminyl radicals generated from sulfenamide precursors

Tandem radical cyclisations of aminyl radicals generated from sulfenamide precursors have been used for the synthesis of pyrrolizidines and other polycyclic nitrogen heterocycles. The aminyl radicals are generated by reaction between sulfenamide precursor

Synthesis of Chiral Vinylglycines

(R)- or (S)-benzyl 4-formyl-2,2-dimethyl-3-oxazolidinecarboxylate (7a) and (R)- or (S)-1,1-dimethylethyl 4-formyl-2,2-dimethyl-3-oxazolidinecarboxylate (7b), readily available from serine, react with Wittig reagents to give alkenes 8.Selective deprotection followed by oxidation of the resulting unsaturated amino alcohols 9 provides vinylglycines 5 of defined configuration (>95percent ee) and double-bond geometry.D-Vinylglycines are obtained from L-serine, and conversely, D-serine gives β,γ-unsaturated amino acids with the L configuration.The double-bond geometry is controlled by the nature of the phosphorous ylide employed.The scope and limitations of this new methodology for the preparation of chiral vinylglycines is examined.

Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues

A series of PGE2, 16,16-dimethyl-PGE2, and PGF(2α), and PGF(2α) analogues modified at the carboxyl terminus with tetrazole, amide, acylurea, imide, and sulfonimide functionalities was evaluated for uterine stimulant, bronchodilator, hypotensive, gastric antisecretory, and diarrheal activity. These compounds were prepared by modification of the Corey prostaglandin synthesis utilizing as a key step condensation of known hemiacetals with the ylide derived from the requisite substituted phosphonium salts. Structure-activity relationships suggest that a proton at the C-1 position appears necessary for agonist activity and the acidity of this proton has a relatively greater influence on activity than pendant steric bulk. Noteworthy are the tissue-selective bronchodilator activity of N-acetyl-PGE2-carboxamide and the selectivity for uterine tissue of N-methanesulfonyl-PGE2-carboxamide, 2-decarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-PGE2, N-acetyl-16,16-dimethyl-PGE2-carboxamide, and N-methanesulfony-PGE2-carboxamide, and N-methanesulfonyl-16,16-dimethyl-PGE2-carboxamide.